PubMed Health⌕ Search

PubMed · 810289

Membrane structure and its relation to haemolysis.

Abstract

Advances in our understanding of the biochemistry, physiology and ultrastructure of the normal erythrocyte membrane have opened up the possibility of characterising congenital or acquired membrane defects in various haemolytic anaemias. The normal red cell membrane can undergo reversible disc-echinocytic or disc-stomatocytic shape changes in response to a wide variety of chemical agents and conditions. These shape changes may become irreversible and, in fact, they may be encountered in different types of haemolytic disease, suggesting that the echinocytic and stomatocytic shape changes represent two fundamental ways in which red cells react to intrinsic and extrinsic insults. Membrane alterations in haemolytic disease can be divided into disorders in which the defect appears to be a primary membrane abnormality, e.g. hereditary spherocytosis and disorders in which membrane damage occurs secondary to internal or external influences, e.g. the membrane alteration in sickled cells. The normal of deformability of the red cell is one of the prime determinants of survival in vivo and thus the geometric relationship of the erythrocyte surface area to cell volume, if decreased, can contribute to haemolysis. Intrinsic changes in membrane deformability or membrane deformability secondary to alterations in the cell haemoglobin may also compromise passage through the microcirculation, particularly through the spleen. Finally, abnormalities of cation permeability and/or lipid composition are found in certain haemolytic states. In each case it is essential to attempt to relate the abnormality described to the manner in which cell properties critical to in vivo survival are compromised in order to understand the pathophysiology.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R I Weed. 1975. Membrane structure and its relation to haemolysis.. https://pubmed.ncbi.nlm.nih.gov/810289/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Autosomal recessive cerebellar ataxias.

Autosomal recessive cerebellar ataxias (ARCA) are a heterogeneous group of rare neurological disorders involving both central and peripheral nervous system, and in some case other systems and organs, and characterized by degeneration or abnormal development of cerebellum and spinal cord, autosomal recessive inheritance and, in most cases, early onset occurring before the age of 20 years. This group encompasses a large number of rare diseases, the most frequent in Caucasian population being Friedreich ataxia (estimated prevalence 2-4/100,000), ataxia-telangiectasia (1-2.5/100,000) and early onset cerebellar ataxia with retained tendon reflexes (1/100,000). Other forms ARCA are much less common. Based on clinicogenetic criteria, five main types ARCA can be distinguished: congenital ataxias (developmental disorder), ataxias associated with metabolic disorders, ataxias with a DNA repair defect, degenerative ataxias, and ataxia associated with other features. These diseases are due to mutations in specific genes, some of which have been identified, such as frataxin in Friedreich ataxia, alpha-tocopherol transfer protein in ataxia with vitamin E deficiency (AVED), aprataxin in ataxia with oculomotor apraxia (AOA1), and senataxin in ataxia with oculomotor apraxia (AOA2). Clinical diagnosis is confirmed by ancillary tests such as neuroimaging (magnetic resonance imaging, scanning), electrophysiological examination, and mutation analysis when the causative gene is identified. Correct clinical and genetic diagnosis is important for appropriate genetic counseling and prognosis and, in some instances, pharmacological treatment. Due to autosomal recessive inheritance, previous familial history of affected individuals is unlikely. For most ARCA there is no specific drug treatment except for coenzyme Q10 deficiency and abetalipoproteinemia.

Abetalipoproteinemia↗

Acanthocytes.

Explore the source record for details and available documents.

Abetalipoproteinemia↗

Assessment of tocopherol metabolism and oxidative stress in familial hypobetalipoproteinemia.

BACKGROUND: Vitamin E supplementation has been recommended for persons with familial hypobetalipoproteinemia (FHBL), a rare disorder of lipoprotein metabolism that leads to low serum alpha-tocopherol and decreased LDL-cholesterol and apolipoprotein (apo) B. We examined the effect of truncated apoB variants on vitamin E metabolism and oxidative stress in persons with FHBL. METHODS: We studied 9 individuals with heterozygous FHBL [mean (SE) age, 40 (5) years; body mass index (BMI), 27 (10) kg/m2] and 7 normolipidemic controls [age, 41 (5) years; BMI, 25 (2) kg/m2]. We also studied 3 children-2 with homozygous FHBL (apoB-30.9) and 1 with abetalipoproteinemia-who were receiving alpha-tocopherol supplementation. We used HPLC with electrochemical detection to measure alpha- and gamma-tocopherol in serum, erythrocytes, and platelets, and gas chromatography-mass spectrometry to measure F2-isoprostanes and tocopherol metabolites in urine as markers of oxidative stress and tocopherol intake, respectively. RESULTS: Compared with controls, persons with FHBL had significantly lower fasting plasma concentrations of total cholesterol [2.4 (0.2) vs 4.7 (0.2) mmol/L], triglycerides [0.5 (0.1) vs 0.9 (0.1) mmol/L], LDL-cholesterol [0.7 (0.1) vs 2.8 (0.3) mmol/L], apoB [0.23 (0.02) vs 0.84 (0.08) g/L], alpha-tocopherol [13.6 (1.0) vs 28.7 (1.4) micromol/L], and gamma-tocopherol [1.0 (0.1) vs 1.8 (0.3) micromol/L] (all P < 0.03). Erythrocyte alpha-tocopherol was decreased [5.0 (0.2) vs 6.0 (0.3) micromol/L; P < 0.005], but we observed no differences in lipid-adjusted serum tocopherols, erythrocyte gamma-tocopherol, platelet alpha- or gamma-tocopherol, urinary F2-isoprostanes, or tocopherol metabolites. CONCLUSION: Taken together, our findings do not support the recommendation that persons with heterozygous FHBL receive vitamin E supplementation.

Abetalipoproteinemia↗